In a 52-week randomized trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.In a 52-week randomized trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.
In cognitively unimpaired older adults, intermediate amyloid burden showed lower dopamine-transporter deviation scores than amyloid-positive status, with an adjusted…In cognitively unimpaired older adults, intermediate amyloid burden showed lower dopamine-transporter deviation scores than amyloid-positive status, with an adjusted difference of −0.582.